Gibson SB - Search Results

1

Buccal cell telomere length is not a useful marker for comorbidities in chronic lymphocytic leukemia.

Yang L, Kost SEF, Beiggi S, Zhang Y, Schmidt R, Nugent Z, Marshall A, Banerji V, Gibson SB, Johnston JB. Yang L, et al. Among authors: gibson sb. Leuk Res. 2019 Nov;86:106220. doi: 10.1016/j.leukres.2019.106220. Epub 2019 Aug 28. Leuk Res. 2019. PMID: 31499418 No abstract available.

2

Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia.

Johnston JB, Kabore AF, Strutinsky J, Hu X, Paul JT, Kropp DM, Kuschak B, Begleiter A, Gibson SB. Johnston JB, et al. Among authors: gibson sb. Oncogene. 2003 Nov 13;22(51):8356-69. doi: 10.1038/sj.onc.1207004. Oncogene. 2003. PMID: 14614459

3

Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications.

Kabore AF, Johnston JB, Gibson SB. Kabore AF, et al. Among authors: gibson sb. Curr Cancer Drug Targets. 2004 Mar;4(2):147-63. doi: 10.2174/1568009043481551. Curr Cancer Drug Targets. 2004. PMID: 15032666 Review.

4

Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia.

Johnston JB, Paul JT, Neufeld NJ, Haney N, Kropp DM, Hu X, Cheang M, Gibson SB. Johnston JB, et al. Among authors: gibson sb. Leuk Lymphoma. 2004 Oct;45(10):2017-27. doi: 10.1080/10428190410001723317. Leuk Lymphoma. 2004. PMID: 15370246

5

Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB.

Hu X, Haney N, Kropp D, Kabore AF, Johnston JB, Gibson SB. Hu X, et al. Among authors: gibson sb. J Biol Chem. 2005 Mar 11;280(10):9498-508. doi: 10.1074/jbc.M410455200. Epub 2004 Dec 23. J Biol Chem. 2005. PMID: 15618220 Free article.

6

Cyclin D expression in chronic lymphocytic leukemia.

Paul JT, Henson ES, Mai S, Mushinski FJ, Cheang M, Gibson SB, Johnston JB. Paul JT, et al. Among authors: gibson sb. Leuk Lymphoma. 2005 Sep;46(9):1275-85. doi: 10.1080/10428190500158797. Leuk Lymphoma. 2005. PMID: 16109604

7

The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.

Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, Gibson SB. Kabore AF, et al. Among authors: gibson sb. Apoptosis. 2006 Jul;11(7):1175-93. doi: 10.1007/s10495-006-8048-9. Apoptosis. 2006. PMID: 16699949

8

The role of TRAIL death receptors in the treatment of hematological malignancies.

Henson ES, Johnston JB, Gibson SB. Henson ES, et al. Among authors: gibson sb. Leuk Lymphoma. 2008 Jan;49(1):27-35. doi: 10.1080/10428190701713655. Leuk Lymphoma. 2008. PMID: 18203008 Review.

9

Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies.

Hu X, Mendoza FJ, Sun J, Banerji V, Johnston JB, Gibson SB. Hu X, et al. Among authors: gibson sb. Cell Signal. 2008 Jun;20(6):1198-208. doi: 10.1016/j.cellsig.2008.02.009. Epub 2008 Feb 19. Cell Signal. 2008. PMID: 18396013

10

Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC.

Ishdorj G, Graham BA, Hu X, Chen J, Johnston JB, Fang X, Gibson SB. Ishdorj G, et al. Among authors: gibson sb. J Biol Chem. 2008 Jun 13;283(24):16818-29. doi: 10.1074/jbc.M710177200. Epub 2008 Apr 11. J Biol Chem. 2008. PMID: 18408217 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

160 results

Search Page

Filters